We have investigated the efficacy of a relatively prolonged course of recombinant leukocyte interferon treatment in 14 chronic HBsAg-, HBeAg-, hepatitis B virus DNA-and DNA polymerasepositive carriers. a-Interferon was administered for 9 weeks. Six of 14 treated carriers have a sustained loss of HBe
Treatment of chronic hepatitis B with recombinant leukocyte interferon and cyanidanol
โ Scribed by Kanai, Koichi ;Morioka, Satoshi ;Nakajima, Takeyuki ;Ishii, Hidemasa ;Tamakoshi, Katsutoshi ;Matsuda, Hiroko ;Matsumoto, Masahiro ;Mizushima, Noriaki ;Takehira, Yasunori
- Publisher
- Springer-Verlag
- Year
- 1988
- Tongue
- English
- Weight
- 645 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0435-1339
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Recombinant human a-interferon is now under intensive investigation as therapy for chronic Type B hepatitis. Recent reports have suggested that prolonged a- interferon therapy may induce autoimmune reactions. We have evaluated the problem of autoimmunity related to a-interferon therapy by testing fo
Eight patients with chronic hepatitis B entered a pilot study of gamma interferon and alpha interferon in combination. Gamma interferon alone had minimal inhibitory effects on serum levels of hepatitis B virus as monitored by serum HBV DNA and DNA-polymerase activity. The drug also gave troublesome